Lenalidomide

Chemical formula: C₁₃H₁₃N₃O₃ Molecular mass: 259.261 g/mol PubChem compound: 216326

Therapeutic indications

Lenalidomide is indicated for:

Newly diagnosed multiple myeloma - maintenance treatment

Population group: only adults (18 years old or older)

Lenalidomide as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily continuously on days 1 to 28 of repeated 28-day cycles until disease progression or intolerance

Myelodysplastic syndromes

Population group: only adults (18 years old or older)

Lenalidomide as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily on days 1-21 of repeated 28-day cycles

Mantle cell lymphoma

Population group: only adults (18 years old or older)

Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25 mg once daily on days 1-21 of repeated 28-day cycles

Newly diagnosed multiple myeloma - combination treatment with bortezomib and dexamethasone

Population group: only adults (18 years old or older)

Lenalidomide in combination with bortezomib and dexamethasone followed by lenalidomide and dexamethasone until disease progression in patients who are not eligible for transplant.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25 mg once daily on days 1-14 of each 21-day cycle for up to 8 cycles

Multiple myeloma with at least one prior therapy

Population group: only adults (18 years old or older)

Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25 mg once daily on days 1-21 of repeated 28-day cycles

Newly diagnosed multiple myeloma - combination treatment with melphalan and prednisone

Population group: only adults (18 years old or older)

Lenalidomide in combination with melphalan and prednisone followed by lenalidomide maintenance in patients who are not eligible for transplant.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

10 mg once daily on days 1-21 of each 28-day cycles for up to 9 cycles

Newly diagnosed multiple myeloma - combination treatment with dexamethasone

Population group: only adults (18 - 65 years old)

Lenalidomide in combination with dexamethasone until disease progression in patients who are not eligible for transplant.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25 mg once daily on days 1-21 of repeated 28-day cycles

Follicular lymphoma Grade 1 – 3a

Population group: only adults (18 years old or older)

Lenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

20 mg once daily on days 1-21 of repeated 28-day cycles for up to 12 cycles of treatment

Contraindications

Lenalidomide is contraindicated in the following cases:

Pregnancy

Pregnancy

Women of childbearing potential

Female of child bearing age

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈